Abstract
We report a case of Epstein-Barr-virus-(EBV-) positive primary cutaneous plasmablastic lymphoma in a human-immunodeficiency-virus-(HIV-) negative, immunocompetent 62-year-old female patient. We postulate that her lymphoma development is due to the longstanding use of pyrimethamine for essential thrombocythemia. This has never been described in the literature.
Highlights
We report a case of Epstein-Barr-virus-(EBV-) positive primary cutaneous plasmablastic lymphoma in a human-immunodeficiency-virus-(HIV-) negative, immunocompetent 62-year-old female patient
We postulate that her lymphoma development is due to the longstanding use of pyrimethamine for essential thrombocythemia
A 62-year-old woman was initially diagnosed with essential thrombocythemia (ET) on the basis of bone marrow aspirate and trephine at age 36 (November 1986), which was later proven to be Janus kinase 2 V617F mutation (JAK2) positive
Summary
Cutaneous Plasmablastic Lymphoma in an Immunocompetent Patient with Long-Term Pyrimethamine Use for Essential Thrombocythemia: A Case Report and Literature Review. We report a case of Epstein-Barr-virus-(EBV-) positive primary cutaneous plasmablastic lymphoma in a human-immunodeficiency-virus-(HIV-) negative, immunocompetent 62-year-old female patient We postulate that her lymphoma development is due to the longstanding use of pyrimethamine for essential thrombocythemia. A 62-year-old woman was initially diagnosed with essential thrombocythemia (ET) on the basis of bone marrow aspirate and trephine at age 36 (November 1986), which was later proven to be Janus kinase 2 V617F mutation (JAK2) positive She was started on hydroxyurea in July 1987 due to platelet counts of >1000 × 109/L and recurrent transient neurological symptoms. In February 2012, she presented to our service with a 3month history of fevers, weight loss, and lethargy She noted a general discomfort and brownish discoloration in her left leg during the same period (Figure 1(a)), which was managed by the vascular surgeons as venous insufficiency.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
